Astellas Pharma's Q4 FY2025 earnings call, held April 27, 2026, revealed a company accelerating its transition away from Xtandi (enzalutamide) dependence through a concentrated set of late-stage pipeline bets. Setidegrasib (ASP3082)'s KRAS G12D degrader franchise, Padcev (enfortumab vedotin)'s bladder cancer expansion, and the broader Claudin 18.2/retinal disease franchises are emerging as key pillars of Astellas’ post-Xtandi growth strategy. The call was held on April 27, 2026.
Key Strategic Signals
[Setidegrasib / KRAS G12D TPD Franchise]: Astellas' targeted protein degradation program has expanded into a multi-indication franchise. A Phase III study in first-line PDAC was initiated during FY2025, and a second Phase III in second-line or later NSCLC is now under preparation following POC achievement in that indication. A follow-on pan-KRAS degrader, ASP5834, has also entered clinical development, executives said.
[ASP2957 / Gene Therapy]: Astellas confirmed a strategic hold on AT132 (resamirigene bilparvovec), its original gene therapy for X-linked myotubular myopathy (XLMM), following the clinical entry of successor ASP2957, which uses a novel muscle-targeted AAV capsid enabling a starting dose approximately 100-fold lower than AT132. Management said the shift was deliberate and that AT132 has been impaired on the balance sheet.
[ASP2138 / Claudin 18.2 Franchise Expansion]: ASP2138 achieved POC in gastric and gastroesophageal junction adenocarcinoma, and Astellas said Phase III initiation in first-line gastric cancer is planned for the first half of FY2026. The company also in-licensed VIR-5500 from Vir Biotechnology as a follow-on asset to reinforce its Claudin 18.2 position.
Analyst Pressure Points
[Setidegrasib vs. Revolution Medicines]: Analysts from UBS and Bernstein pressed management on whether Revolution Medicines' pan-KRAS inhibitor data, presented at AACR in April, represented a competitive threat to setidegrasib's KRAS G12D-specific approach. Chief R&D Officer Tadaaki Taniguchi acknowledged Revolution's data as favorable for the KRAS target overall, but argued setidegrasib's specificity translates to a cleaner safety profile, particularly lower skin and gastrointestinal adverse events, and easier combinability with chemotherapy in PDAC. He conceded the efficacy differentiation would only be resolved in late-phase data.